Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Brugada syndrome Indication Strategy Report 2026: SCN5A, Trials and Deals
23 July 2026
2026 Brugada syndrome strategy: epidemiology, SCN5A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Catecholaminergic polymorphic ventricular tachycardia Indication Strategy Report 2026: RYR2, Trials and Deals
23 July 2026
2026 Catecholaminergic polymorphic ventricular tachycardia strategy: epidemiology, RYR2 biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Long QT syndrome Indication Strategy Report 2026: KCNH2, Trials and Deals
23 July 2026
2026 Long QT syndrome strategy: epidemiology, KCNH2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Pulmonary veno-occlusive disease Indication Strategy Report 2026: BMPR2, Trials and Deals
23 July 2026
2026 Pulmonary veno-occlusive disease strategy: epidemiology, BMPR2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Essential hypertension Indication Strategy Report 2026: AGT, Trials and Deals
23 July 2026
2026 Essential hypertension strategy: epidemiology, AGT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Sitosterolemia Indication Strategy Report 2026: ABCG5, Trials and Deals
23 July 2026
2026 Sitosterolemia strategy: epidemiology, ABCG5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Familial chylomicronemia syndrome Indication Strategy Report 2026: APOC3, Trials and Deals
23 July 2026
2026 Familial chylomicronemia syndrome strategy: epidemiology, APOC3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital hyperinsulinism Indication Strategy Report 2026: KATP, Trials and Deals
23 July 2026
2026 Congenital hyperinsulinism strategy: epidemiology, KATP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary carnitine deficiency Indication Strategy Report 2026: SLC22A5, Trials and Deals
23 July 2026
2026 Primary carnitine deficiency strategy: epidemiology, SLC22A5 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Carnitine palmitoyltransferase II deficiency Indication Strategy Report 2026: CPT2, Trials and Deals
23 July 2026
2026 Carnitine palmitoyltransferase II deficiency strategy: epidemiology, CPT2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency Indication Strategy Report 2026: HADHA, Trials and Deals
23 July 2026
2026 Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency strategy: epidemiology, HADHA biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Very long-chain acyl-CoA dehydrogenase deficiency Indication Strategy Report 2026: ACADVL, Trials and Deals
23 July 2026
2026 Very long-chain acyl-CoA dehydrogenase deficiency strategy: epidemiology, ACADVL biology, clinical competition, recent deals, unmet need and market…